Rovas, A.; Neumann, J.K.; Drost, C.C.; Vollenberg, R.; Thölking, G.; Fobker, M.; Witzenrath, M.; Kümpers, P.; AGAMOTTO Study Group; CAPNETZ Study Group.
Analysis of Urinary Glycosaminoglycans to Predict Outcome in COVID-19 and Community-Acquired Pneumonia—A Proof-of-Concept Study. J. Clin. Med. 2023, 12, 5269.
https://doi.org/10.3390/jcm12165269
AMA Style
Rovas A, Neumann JK, Drost CC, Vollenberg R, Thölking G, Fobker M, Witzenrath M, Kümpers P, AGAMOTTO Study Group, CAPNETZ Study Group.
Analysis of Urinary Glycosaminoglycans to Predict Outcome in COVID-19 and Community-Acquired Pneumonia—A Proof-of-Concept Study. Journal of Clinical Medicine. 2023; 12(16):5269.
https://doi.org/10.3390/jcm12165269
Chicago/Turabian Style
Rovas, Alexandros, Julia Katharina Neumann, Carolin Christina Drost, Richard Vollenberg, Gerold Thölking, Manfred Fobker, Martin Witzenrath, Philipp Kümpers, AGAMOTTO Study Group, and CAPNETZ Study Group.
2023. "Analysis of Urinary Glycosaminoglycans to Predict Outcome in COVID-19 and Community-Acquired Pneumonia—A Proof-of-Concept Study" Journal of Clinical Medicine 12, no. 16: 5269.
https://doi.org/10.3390/jcm12165269
APA Style
Rovas, A., Neumann, J. K., Drost, C. C., Vollenberg, R., Thölking, G., Fobker, M., Witzenrath, M., Kümpers, P., AGAMOTTO Study Group, & CAPNETZ Study Group.
(2023). Analysis of Urinary Glycosaminoglycans to Predict Outcome in COVID-19 and Community-Acquired Pneumonia—A Proof-of-Concept Study. Journal of Clinical Medicine, 12(16), 5269.
https://doi.org/10.3390/jcm12165269
